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Incidental and Metastatic Adrenal Masses
Massimo Mannelli,a,b Stefano Colagrande,c Andrea Valeri,d and Gabriele Parentie
In the last decades discoveries of adrenal masses incidentally during the course of diagnostic
procedures for unrelated disorders (incidentalomas) have become progressively more frequent.
The clinician in this position must answer two main questions: Is the mass benign or malignant?,
and To what extent is the adrenal secretion altered? To come to a clinical decision, several
diagnostic tools need to be engaged, starting with an accurate and correct radiological evaluation
and a hormonal assessment of the adrenal function. When necessary, other diagnostic procedures
such as functional imaging and fine-needle biopsy (FNB) can be considered in selected cases.
Surgical removal is recommended for clinically relevant hypersecretory masses, as well as for
masses suspected to be malignant. Most frequently, adrenal incidentalomas (AIs) are represented by
benign cortical adenomas, a subset of which causes a mild hypercortisolism, known as subclinical
Cushing’s syndrome (SCS). The criteria to define this syndrome, as well as its treatment, are still
debated and controversial. AIs that are not surgically removed should be re-examined in time to
exclude a supervening increase in size or function. Follow-up criteria have not been established.
Laparoscopic surgery is the recommended procedure to remove benign masses. The surgical
procedure for adrenal malignancies is still debated.
Semin Oncol 37:649-661. © 2010 Published by Elsevier Inc.
The widespread use of abdominal radiologicalexaminations, such as ultrasonography (US),computed tomography (CT), and magnetic res-
onance imaging (MRI), has caused the serendipitous
discovery of adrenal masses called incidentalomas
(AIs).1,2 In autopsy studies, the mean incidence of ad-
renal masses was found to be approximately 6%.3 This
finding seems to be confirmed by the 4% incidence of
adrenal masses detected at CT.4 Similarly to the thyroid
gland, human adrenals have been shown to develop
adrenal nodules with increasing age, so that after 70
years the probability of developing an adrenal nodule is
about 7%.2,3 As a consequence, in the last two decades,
clinicians have faced a new epidemic, represented by
the AIs. The biological nature and the clinical relevance
can be very different among AIs (Table 1).
As AIs are, by definition, discovered during radio-
logical examinations performed for signs or symp-
toms unrelated to adrenal diseases,5 the clinical pic-
ture is generally of little or no help in suggesting the
nature of the lesion6–8 and the diagnostic pathway
starts from the study of the radiological image.9
Therefore, an expert radiologist and a technically
updated radiological apparatus (CT or MRI) are rec-
ommended for a correct approach. Nonetheless, cli-
nicians need to collect an accurate medical history
and to perform a meticulous clinical examination of
the patient in search of very mild symptoms or signs
that might suggest a slight, initial derangement of the
adrenal function (Table 2). The task is not easy,
especially because the signs and symptoms of a mild
adrenal disorder are undistinguishable from those
largely present in the general middle-aged or older
population, such as obesity, fatigue, osteoporosis,
hypertension, glucose intolerance, and diabetes,
which are generally related to the so-called meta-
bolic syndrome.10–15
The clinician must answer two main questions: Is
the mass dangerous (benign or malignant)?; and, Is the
mass responsible for a clinically relevant disorder of the
adrenal function? The final decision of whether to sur-
gically remove the AI or not depends on the answers to
these two questions.
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IMAGING
AIs are generally discovered at US or CT examina-
tions. CT easily depicts normal glands and can accu-
rately detect and characterize adrenal nodules. When
CT characterization is unsatisfactory, MRI may be of
help due to its great contrast resolution and its capa-
bility to distinguish normal and pathological tissues, as
well as cyst, edema, necrosis, hemorrhage, vascularity,
and cellular density.
Radiological criteria include size, morphology, CT
density, MRI signal characteristics, and enhancement
after administration of iodinated or gadolinium chelates
contrast agents (CAs).
At first assessment, CT and MRI allow the diagnosis
and classification of benign lesions, such as myelolipo-
mas, cysts, bilateral hyperplasia, and, in most cases,
hematomas (Table 3).
Myelolipoma
Myelolipoma is typically a nonfunctional, unilateral,
asymptomatic, benign lesion with variable content of
myeloid and fat tissue, whose presence (30
Hounsfield units [HU]) is diagnostic16–18 (Figure 1). De-
pending on the vascularization of the myeloid portion,
sometimes an enhancement can be found at CT or MRI
examination; focal calcifications are detectable in ap-
proximately 25% of cases; In large myelolipomas, hem-
orrhages may occur and blood (heme) catabolites are
usually recognizable.19,20
Cyst and Pseudocyst
Adrenal cysts are uncommon. Pseudocysts and en-
dothelial (lymphangiomatous) cysts are more common
than true epithelial cysts, which are rare, accounting
for less than 15%.21,22 Endothelial and simple cysts are
easily recognizable for subtle, non-enhancing walls,
fluid content, and infrequent, slight, peripheral calcifi-
cations.17,22–24 Sometimes pseudocysts have thick walls
with internal septa and calcifications.17 Their content
usually shows a low density but a higher density may
be caused by hemorrhages or protein debris. When
they are large and composed by a complex tissue mass,
the differential diagnosis with malignancies or a
chronic abscess can be difficult.19
Hyperplasia
The adrenal glands are generally both enlarged and
usually maintain their normal shape, with smooth sur-
Table 1. Nature of Incidental Adrenal Masses
Common incidental adrenal masses
Non-hypersecreting adenomas (benign, clinically silent)
Cortisol-secreting adenomas (benign, subclinical Cushing’s syndrome)
Aldosterone-secreting adenomas (benign, hypertension)
Carcinoma (malignant, nonsecreting or steroi-secreting; sometimes flank pain, weight loss)
Pheochromocytoma (mostly catecholamine-secreting, mostly benign, mostly with hypertension)
Metastasis (sometimes bilateral, possible cause of adrenal insufficiency)
Myelolipoma (benign, generally clinically silent)
Cysts (benign, clinically silent)
Hematomas (benign, possible transient flank pain)
Uncommon incidental adrenal masses
Lipoma, ganglioneuroma, ganglioneuroblastoma, neurofibroma, schwannoma, lymphoma, tubercolosis,
histoplasmosis
Pseudoadrenal masses
Gastric diverticulum, renal cyst, renal tumor, splenic lobulation, splenic aneurisma, pancreatic mass
Table 2. Correlation Between Type of Adrenal
Hypersecretion and Clinical Signs
Glucocorticoids Obesitiy
Impaired glucose
tolerance/diabetes
Hypertension
Osteoporosis
Mineralcorticoids Hypertension
Impaired glucose
tolerance/diabetes
Catecholamines Hypertension
Impaired glucose
tolerance/diabetes
Androgens Oligo-amenorrhea
Hirsutism
Estrogens Erectile dysfunction
Gynecomastia
Irregular menses
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face, although sometimes a unilateral nodular enlarge-
ment may occur.25
Hematoma
Adrenal hematomas are caused by traumatic and
nontraumatic events, including sepsis, burns, hypoten-
sion crises, neonatal stress, coagulation disorders, and
adrenal tumors, such as pheochromocytoma (most
common cause of bleeding), myelolipoma, and adreno-
cortical carcinoma. Hemorrhages in metastases and in
adenomas are uncommon.20 Adrenal hemorrhage may
be clinically silent, with spontaneous resolution; how-
ever, it can evolve in a pseudocyst.26 With the excep-
tion of patients with coagulopathies,27 most hemor-
rhages are unilateral, usually on the right site due to the
drainage of the right adrenal vein into the inferior vena
cava.26 CT can be used to detect and characterize an
acute hematoma because of the high density of bleed-
ing clot. Conversely, subacute and chronic hematomas
are recognizable on MRI. In the subacute phase
(roughly from 7 to 45 days after onset), hematomas are
hyperintense on T1- and T2-weighted images due to the
presence of meta-hemoglobin, a natural paramagnetic
agent that improves T1 signal intensity. In the chronic
phase, a hypointense rim can be detected on T1- and
T2-weighted acquisitions as a consequence of hemosid-
erin deposition, a natural super-paramagnetic agent
that decreases T2 signal intensity. It should be under-
scored that hematoma is frequently multilocular, and
each locule may have different signal intensities be-
cause of the differing evolution of the heme.
The radiologist and the clinician must be aware that
the hematoma may be the consequence of the bleeding
of a malignancy, hidden by the strong dishomogeneity
and signal intensity of the heme collection.
Adenoma
The above-described pathological entities are usu-
ally confidently recognizable, but also relatively rare on
imaging studies, where the most frequent finding is a
cortical adenoma, which represents up to 80% of the
adrenal masses detected at US, CT, and MRI.8
Adrenal adenomas are usually small (3 cm), oval,
with smooth, well-defined margins and lipid content
(Figure 2). Calcifications, necrosis, and hemorrhage are
atypical, although they can occur, particularly in larger
lesions.19 As a general rule, roughly 80% to 90% of
adrenal nodules smaller than 3 cm are benign, while,
conversely, the rate of malignancies increases with
larger sizes.
As size cannot per se discriminate between benign
and malignant masses, additional criteria have to be
adopted, among which the lipid content is of the most
value, due to the typical high intracellular lipid content
Table 3. Proposed Flowchart for the Radiological First Approach Evaluation of an Adrenal Incidentaloma
------------------------------------------------------------------------------------------------------------------------
First rule out of easily recognizable (characterizable) adrenal masses
Cyst and pseudocyst
Hyperplasia
Myelolipoma
Acute and sub-acute hematoma 
If  mass shows all the following criteria: (< cm 3, oval shape, regular margins, lipid content, mild/none enhancement)
Adenoma
If only one of the above reported criteria is absent (> cm 3/round/irregular margins/no lipid content/various enhancement),
the adrenal mass may not be an adenoma  and needs further clinical examination, in the suspect of:      
If round, bright T2, strong enhancement, (hypertension)
Pheocromocytoma 
If round, irregular, heterogeneous, hypo-T1/hyper-T2, peripheral enhancement, sometimes bilateral
Metastasis 
If round, regular, homogeneous, hypo-T1/hyper-T2, mild enhancement, frequently bilateral with lymph node involvement:
Lymphoma 
If round, irregular, heterogeneous, hypo-T1/hyper-T2, peripheral enhancement (hypercortisolism/virilization):
Adrenocortical cancer 
If round, irregular, heterogeneous, hypo-T1/hyper-T2, peripheral enhancement (calcification/hemorrhage/necrosis young children)
Neuroblastoma
----------------------------------------------------------------------------------------------------------------------------------------------------------------
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of adrenal adenomas. Several criteria have been pro-
posed to detect and measure the lipid content of adre-
nal masses.28 On unenhanced CT, density measurement
seems to be simple, accurate, and reliable: if the mass
has a density 10 HU, diagnosis of adenoma has a 74%
sensitivity and 96% specificity.16,23 On enhanced CT,
the density measurement 30 minutes after CA adminis-
tration yields 100% specificity and sensitivity (adeno-
mas 37 HU; non-adenomas 41 HU).29 Nevertheless,
other cut-off values have been proposed.28
The lipid content of an AI also can be detected by
MRI, using a technique based on the chemical shift
phenomenon. This technique allows the acquisition of
two sequential images, with and without fat/lipid signal
suppression, respectively. If the nodule has a high
fat/lipid content, as in the majority of adenomas, a
signal drop is evidenced between two sequential im-
ages. In the case of metastases or nodules other than
adenomas, because of their poor lipid content, signal
drop is irrelevant.30,31
Therefore, in the absence of a history of malignancy,
a small, oval, homogeneous, lipid-containing mass,
with regular margins showing mild or no enhancement
can be confidently diagnosed as adenoma (benign inci-
dentaloma) and might not require additional radiologi-
cal investigation. If the lipid content of the mass is
slight or absent, a 6- to 12-month imaging follow-up is
generally considered sufficient to diagnose a “not-
evolving” (or steady) adrenal lesion. Alternatively, 131I-
6--iodomethyl-19-norcholesterol (NP-59) scintigraphy
may be performed (see below).
Signs to be considered suspicious for primary or
secondary malignancy (metastasis, lymphoma, adreno-
cortical carcinoma) or pheochromocytoma include size
larger than 3 cm, no lipid content, heterogeneous in-
ternal density/signal intensity, and strong/irregular en-
hancement after CA administration. In such cases, in-
vestigations in addition to hormonal assessment are
recommended.
Metastasis
The adrenal glands represent a common site of met-
astatic disease, because of their high vascularity. Com-
mon tumors, including carcinomas of the breast, lung,
kidney, colon, esophagus, pancreas, liver, and stom-
ach, as well as melanoma, may metastasize to the ad-
renal gland.6,7 The prevalence of adrenal metastases in
patients with extra-adrenal cancers ranges from 32% to
73% in different series.7,10,16
When affecting both adrenals, metastases may cause
adrenal failure. Metastases appear, on average, as large,
heterogeneous, poorly defined masses with a thick
enhancing rim on contrasted studies.32 On MRI, metas-
tases have nonspecific low T1/high T2 signal intensity,
without drop signal on opposed phase (Figure 3). Hem-
orrhages and calcifications are rare.
When small, metastatic lesions can appear homoge-
neous, well-defined, and with low density. The diagno-
sis is difficult in these cases.
It should be emphasized that benign adrenal lesions
cannot be differentiated from malignancies using the
newest MRI techniques, such as diffusion-weighted im-
aging. This technique is based on the assumption that
in malignancies free diffusion of water molecules is
restricted due to abnormal vascularity and increased
tissue cellular density. Unfortunately, free water diffu-
sion is not different between malignant and benign
adrenal lesions. Therefore, diffusion-weighted imaging
cannot be used to classify adrenal masses and chemical
shift imaging is still required using MRI to differentiate
adrenal adenomas from metastases.33,34
Figure 1. Right adrenal myelolipoma. Unenhanced (A)
and enhanced (B) CT study. The tumor is well visible (A, B)
as a very low-density mass (white arrow) due to the fat
tissue content, whose presence is diagnostic. Within the
mass, a more dense nodule is recognizable (white arrow-
head), referable to the myeloid portion, with some en-
hancement after iodinated CA administration.
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Patients with a history of extra-adrenal malignancy
and the presence of an adrenal mass should undergo
the same diagnostic procedure as patients with an AI
(biochemical and radiological evaluation). Neverthe-
less, in patients with clinical and radiological suspi-
cions of adrenal metastases, a fine-needle biopsy (FNB)
(see below) and a positron-emission tomography (PET)
with 18F-fluorodeoxyglucose (18F-FDG) may be helpful
before considering a surgical approach.
Adrenocortical Carcinoma
Primary adrenal carcinoma is a rare lesion. Similarly
to metastases, it can rarely be represented by a small,
homogeneous lesion, but in the vast majority of cases,
the first imaging presentation is constituted by a great,
inhomogeneous mass, with necrosis, hemorrhages, and
calcifications.35 In any case, even when presenting as a
small nodule, on unenhanced MRI it displays a hetero-
geneous nonspecific low T1/high T2 signal intensity
and a peripheral irregular enhancement after CA ad-
ministration on both CT and MRI (Figure 4).36
Neuroblastoma
Neuroblastomas are mostly located in the adrenal
glands and are the most common adrenal lesions in
children.19 Neuroblastomas commonly contain calcifi-
cations, necrosis, or hemorrhage. On MRI they appear
as heterogeneous nonspecific low T1/high T2 signal
intensity nodules.37 After CA administration they
present an intense enhancement, mainly at the periph-
ery or where necrosis is absent.
Pheochromocytoma
Pheochromocytomas are highly vascular masses,
with a high intracellular water content and frequent
Figure 2. Right adrenal adenoma. Unenhanced T1-weighted in-phase (A) and out-phase (B), T2-weighted (C), and enhanced
T1-weighted (D) MRI axial acquisitions. A small (diameter 1.5 cm), oval mass with smooth, well-defined margins (white
arrow) is detectable (A–D). The nodule has low density due to its lipid content. In fact, in the sequences based on the chemical
shift phenomenon (A, B), the nodule shows an evident signal drop between in-phase (A) and out-phase (B) acquisitions. The
cellular density and water content is poor as evidenced by low signal intensity on T2-weighted acquisition (C). Mild
enhancement is demonstrable after gadolinium chelates CA administration, due to low vascularization (D).
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intratumoral cystic lesions.38 These characteristics ac-
count for their typical but nonpathognomonic high
signal on T2-weighted imaging and strong enhance-
ment after CA administration. Reduced T2 signal inten-
sity can result from internal hemorrhages.39
Small pheochromocytomas may appear homoge-
neous but usually they are greater than 3 cm and
present internal areas of necrosis or hemorrhage
(Figure 5), sometimes with fluid–fluid levels.40,41
Similarly to other nonionic iodinated CAs,42 gado-
linium chelates do not cause catecholamine release
from the tumor, and can be administered to patients
with pheochromocytoma without requiring adrener-
gic blockade before scanning.
HORMONAL EVALUATION
The majority of AIs are non-hypersecreting adre-
nal masses. In a large multicentric study including
1,004 AIs, 85% could be classified as non-hyperfunc-
tioning; among the hyperfunctioning AIs, 9.2% were
classified as causing subclinical Cushing’s syndrome
(SCS), 4.2% as pheochromocytomas, and 1.6% as
aldosterone-producing adrenal masses.8 By definition,
many patients with AI are asymptomatic or present
only with nonspecific signs or symptoms. Table 2
shows the possible link between signs or symptoms
and hormonal hypersecretion. Because of the uninfor-
mative clinical picture, the secretory activity of the
incidental adrenal masses has to be assessed by hor-
mone measurements in plasma, urine, or saliva.
Glucocorticoid Secretion
It is now widely accepted that patients with SCS can
be diagnosed by the finding of two or more abnormal
results in tests evaluating the hypothalamus-pituitary-
adrenal axis.8 The biochemical evaluation of glucorti-
Figure 3. Left adrenal metastasis from lung carcinoma. Unenhanced T1-weighted in-phase (A) and out-phase (B), fat
suppressed T2-weighted (C), and enhanced T1-weighted (D) MRI axial acquisitions. A 2-cm, round mass with well-defined
margins (white arrow) is evident (A–D). The nodule has low signal intensity and, in the sequences based on the chemical shift
phenomenon (A, B), it does not show an apparent signal change between in-phase (A) and out-phase (B) acquisitions. The
cellular density, water content, and vascularization are evidenced by medium–high signal intensity on T2-weighted acquisition
(C) and by clear enhancement after gadolinium chelates CA administration (D).
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coid function can be performed by one of the following
tests: urinary free cortisol (UFC), 1 mg overnight dexa-
methasone suppression test (DST), or midnight salivary
cortisol. To detect the presence of hypercortisolism,
each test (alone or variably associated) can be per-
formed as a first-line diagnostic approach. UFC levels
are not affected by changes in corticosteroid-binding
globulin and thus represent an integrated measure of
unbound circulating cortisol over 24 hours. Normal
UFC values exclude chronic hypercortisolism with
high probability, while a fourfold increase is diagnostic
of Cushing’s syndrome.43 The 1-mg DST is performed
by administration of 1 mg of dexamethasone late in the
evening (11 PM) followed by measurement of serum
cortisol at 8 AM on the following day. The optimal
cut-off of cortisol after a 1-mg DST is still debated: a
value 5 g/dL (138 nmol/L) is considered diagnostic
for glucocorticoid hypersecretion,44 but a threshold of
1.8 g/dL (50 nmol/L) has been suggested45 to increase
diagnostic sensitivity. This lower cut-off is particularly
useful in detecting more subtle autonomous cortisol
hypersecretion, or SCS. Midnight salivary cortisol rep-
resents the most recent test used in the screening of
hypercortisolism and is performed by collecting a saliva
sample late in the evening (between 11 PM and mid-
night) on two different occasions. Salivary cortisol is
highly correlated with unbound plasma cortisol levels.
The normal reference values are assay-dependent and
should be established for each laboratory.46 Some in-
vestigators have shown that elevated midnight salivary
cortisol levels are a useful and simple screening test for
hypercortisolism, with a sensitivity and specificity
reaching 90% to 95%.47 In patients without clearly di-
agnostic laboratory results, a classical DST (Liddle test:
2 mg/d oral dexamethasone for 2 days) may be per-
formed.
ACTH assay represents a second-line diagnostic ap-
proach: when hypercortisolism, either overt or subclin-
ical, has been established, low or suppressed ACTH
levels will confirm the adrenal origin of hypercorti-
solism. In patients with SCS, cortisol secretion is, by
definition, only slightly increased, Nonetheless, an as-
sociation between SCS and an increased risk of obesity,
diabetes, hypertension, and osteoporosis cannot be
excluded.48–52 Although an Italian multicentric study
performed in patients with AI did not demonstrate a
significant association between SCS and increased
morbidity,8 long-term follow-up in a large number of
patients with SCS is necessary to establish the real
clinical impact of this mild hormonal alteration.
In patients undergoing surgery for an AI, the dem-
onstration of a subtle cortisol hypersecretion is also
important to avoid an acute adrenal insufficiency cri-
Figure 4. Left adrenal carcinoma. Unenhanced (A) and enhanced CT study in arterial (B) and venous (C, D) phases. A large
mass with irregular shape and borders (white arrows) is shown (A–D). Some calcifications (white arrowhead) are detectable on
unenhanced examination (A). After administration of iodinated CA, the mass demonstrates uneven enhancement due to
heterogeneous content and pathological vascularization (B–D).
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sis53 possibly caused by the removal of an unrecognized
“pre-toxic” nodule.
Although rare, progression from a non-hyperse-
creting to a hypersecreting adrenal adenoma is al-
ways possible. Therefore, there is general agreement
that a hormonal evaluation should be performed an-
nually for 4 years in patients diagnosed with an
adrenal adenoma.5,54,55
Mineralocorticoid Secretion
Current evidences suggest that the prevalence of
primary aldosteronism (PA) is higher than previously
thought, accounting for up to 12% of hypertensive
patients.56 The introduction of the serum aldosterone
(SA)/plasma renin activity (PRA) ratio (ARR) as a
screening test among hypertensive patients probably
accounts for this consistent increase. The use of ARR is
considered more convenient than separate determina-
tion of PRA and plasma and/or urinary aldosterone. In
fact, a normal or normal/high value of plasma aldoste-
rone can be inappropriately high in the presence of a
suppressed renin-angiotensin system, thus suggesting a
PA even in its milder forms and/or in the absence of
hypokalemia. The optimal cut-off of ARR is still debated
and ranges from 20 to 50 when SA and PRA are ex-
pressed in ng/dL and ng/mL/h, respectively.57 The eval-
uation of ARR should be performed in the absence of
antihypertensive therapy, but if a medical treatment is
mandatory, calcium channel blockers and/or alfa-block-
ers can be permitted.
It is generally agreed that a high ARR is not diagnos-
tic of PA and that a confirmatory test is needed for a
final diagnosis. The most widely recommended sup-
pression tests are those using oral fludrocortisone, oral
captopril, or intravenous as well as oral saline load.
Sexual Steroid Secretion
Sex hormone–secreting adrenal masses are rare.
However, dehydroepiandrosterone sulfate (DHEAS)
measurement is recommended in patients with AI. The
production of androgens is more frequent in adreno-
cortical cancer than in adrenal adenoma, so sex steroid
hypersecretion should be possibly considered as a bio-
chemical index of malignancy. When suspecting an
adrenocortical cancer, as well as in the presence of
hirsutism or virilization, testosterone and delta-4-andro-
stenedione should be measured as well.
In SCS a low level of DHEAS is frequently found, but
Figure 5. Left adrenal pheochromocytoma. Unenhanced T1-weighted (A), T2-weighted (B), and enhanced T1-weighted (C)
MRI axial acquisitions; enhanced CT study in late venous phase (D). A large, oval mass with regular margins (white arrows) is
shown (A–D). Previous internal subacute hemorrhage explains medium–high signal intensity on T1-weighted acquisition
(white arrowheads) due to the presence of meta-hemoglobin, a natural paramagnetic agent. The colliquative, hydrated
necrosis consequent to the hemorrhage is also demonstrated by the high signal intensity on T2-weighted image (B), by the
absence of internal enhancement after gadolinium chelates CA administration (C), and by the same pattern on enhanced CT
study (D).
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its diagnostic value is poor because of its physiological
decrease with age.58
An exaggerated 17OH-progesterone (17OHP) re-
sponse to ACTH stimulation is commonly observed in
patients with AI, but the clinical significance of this
biochemical response is not clear. It has been hypoth-
esized that a latent 21-hydroxylase deficiency might
cause adrenal growth, predisposing to adenoma forma-
tion,57 but it has to be considered that the enhanced
17OHP response also might depend on an altered in-
tratumoral steroidogenesis.59 Therefore, basal and stim-
ulated 17OHP measurements should be restricted to
patients with bilateral adrenal masses.
Measurement of 17-estradiol is very rarely indi-
cated and should be reserved to male patients with an
AI associated with gynecomastia and/or erectile dys-
function.
Catecholamine Secretion
The diagnosis of pheochromocytoma (or secreting
paraganglioma) is based on laboratory data demonstrating
an increase of catecholamines or of their metabolites in
plasma or urine. Until recently, the recommended initial
test for the diagnosis of pheochromocytoma was 24-hour
urine-free catecholamines (adrenaline and noradrena-
line).60 In the last two decades, many investigators have
agreed that plasma free metanephrines or urine decon-
jugated differential metanephrines should be recom-
mended as the biochemical tests for pheochromocy-
toma screening.61 The validity of metanephrines as the
preferred analytes has been supported by several large
case control studies demonstrating their higher sensi-
tivity in comparison to catecholamines or vanilman-
delic acid.62,63 The higher sensitivity is mainly due to
the longer half-life of metanephrines and to their non-
episodic production by the tumor where catecholamines
are continuously converted to metanephrines by the
high methyltransferase activity of the chromaffin tis-
sue.64 Due to the very low number of false negative
results, a normal value in plasma or urinary metaneph-
rines makes the diagnosis of pheochromocytoma
highly unlikely, thus avoiding additional costly investi-
gations.
NUCLEAR MEDICINE EVALUATION
In a very limited number of cases, when radiology is
not able to reasonably classify/characterize an adrenal
mass as benign or malignant, functional imaging can be
of help.
131I-6--iodomethyl-19-norcholesterol (NP-59) scin-
tigraphy has a high positive predictive value for the
detection of adenoma, thus classifying the incidenta-
loma as benign. In fact, other adrenal lesions, including
adrenocortical carcinoma, do not concentrate the trac-
er.65 Nevertheless, its use should be limited to very
select cases; false positive results in case of secreting
adrenal cancer are possible.
18F-FDG-PET is another functional imaging modality
used to differentiate benign from malignant adrenal
lesions. In fact, 18F-FDG is trapped by metabolically
active malignant lesions, whereas most benign lesions
fail to concentrate the isotope.65–67 Therefore, 18F-FDG-
PET will be positive for primary or secondary adrenal
malignancies, although false negative results can be
found and, conversely, an increased radiotracer uptake
can be registered in pheochromocytomas, which are,
for the vast majority, benign lesions.
Scintigraphy using 123I-metaiodobenzylguanidine
(MIBG) is the most widely used tool to localize a pheo-
chromocytoma/paraganglioma after a biochemical di-
agnosis or to search for chromaffin metastatic lesions.68
PET with 18F-fluorodopamine, 18F-fluorodopa, or 11C-
hydroxyephedrine are more expensive functional im-
aging methods that may be used as alternatives to
123I-MIBG.69–72
ADRENAL BIOPSY
The accuracy of the available imaging techniques in
characterizing AI greatly reduces the necessity for ad-
renal FNB. Its use is limited to distinguishing an adrenal
metastasis from an extra-adrenal malignancy. This pro-
cedure does not allow differentiation of a benign adre-
nal adenoma from an adrenal adrenocortical carcinoma
and must not be performed before having excluded the
possibility of a pheochromocytoma.
Image-guide FNB is rather safe with a complication
rate of less than 3%.6 The most common complications
include hematoma, abdominal pain, hematuria, pancre-
atitis, and pneumothorax. The possibility of a diffusion
of cancer cells along the needle track also should be
considered.2,73,74
FINAL DECISION
The decision on whether to suggest the surgical
removal of the AI depends on the results of the afore-
mentioned diagnostic procedures (Figure 6). Surgery is
recommended for hypersecreting and/or malignant (or
suspected malignant) adrenal masses. For AI classified
by the radiologist as benign adrenocortical adenomas,
the decision depends on the laboratory results. Very
often the associated functional derangement is minimal
and the choice between surgery or medical treatment
is difficult, especially in elderly people where an accu-
rate evaluation of the risk/benefit ratio is mandatory.
The size of the AI is generally considered of upmost
value in the final decision, as there is a positive corre-
lation between mass diameter and malignancy and a
diameter of 4 cm or more is considered an index of
suspicion. Nonetheless, in the authors’ opinion, size
cannot be considered an index of absolute value. In
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fact, several AI, radiologically classified as benign, like
myelolipomas, cysts, and hematomas, may be larger
than 4 cm. Moreover, there is no doubt that a solid AI
showing an increased diameter at follow-up should be
removed, independent of its size. A summary of the
adrenal masses to be or not to be surgically removed is
reported in Table 4.
In conclusion, the final decision on whether to pro-
Figure 6. Suggested simplified flow-chart for the clinical management of incidental adrenal masses. FNB, fine-needle biopsy.
Table 4. Suggested Criteria for Surgical Therapy of Adrenal Masses
Indications Contraindications
Hypersecreting Not functioning
- Aldosterone-secreting adenoma (Conn’s syndrome.) - Benign, small not growing
- Cortisol-secreting adenoma - Not functioning stage IV adrenocortical carcinoma
- Bilateral adrenocortical hyperplasia (otherwise
incurable ACTH-dependent Cushing’s syndrome) Metastases
- Pheochromocytoma -Bilateral
- Multiple (also extra-adrenal)
Adrenocortical carcinoma
- Stage I-III
- Stage IV if functioning for debulking
Metastases
- Solitary
- Monolateral
Other suspected malignancies
(for size or radiological characteristics)
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ceed to surgery or not stems on several independent
criteria like the radiological characteristics of the mass,
the results of the hormonal screening, the results of
additional diagnostic procedures such as functional im-
ages and/or FNB, and evidence of a stable or a growing
diameter. All of these criteria also should be considered
in the light of other influencing clinical parameters like
age, general condition, and comorbidities to correctly
evaluate the risk/benefit ratio of the therapeutic deci-
sion.
SURGICAL APPROACH
In the last decades, technological developments in
instrumentation and improvements in surgical tech-
niques have greatly modified adrenal surgery. At
present, the less invasive laparoscopic technique is
recommended as the first choice approach to adrenal
surgery.75,76
Different laparoscopic surgical approaches have
been proposed to perform adrenalectomy. The lateral
trans-peritoneal approach is the most frequently per-
formed procedure for unilateral adrenalectomy, since it
permits easy access to the retroperitoneal space77 and
a better exposition of the retroperitoneal surgical field
once the patient is positioned on the controlateral
flank. The retroperitoneal approach is a more recently
proposed alternative procedure that allows direct ac-
cess to the adrenal gland, without mobilizing other
organs. It is indicated for bilateral adrenalectomy be-
cause it may significantly reduce the operative times by
avoiding repositioning of the patient. The trans-abdom-
inal anterior approach is very seldom used and is re-
served for bilateral adrenalectomy.
Laparoscopic surgery is recommended to remove
any adrenal mass up to about 10 cm in size, with the
size limit depending on the experience of the surgical
team. The use of laparoscopic surgery to remove adre-
nocortical cancer is still debated. Nonetheless, in the
authors’ opinion, its use should be permitted to remove
suspected adrenal cancers that, at radiology, do not
present infiltration of the surrounding organs. The lapa-
roscopic technique is indicated also for sparing adre-
nocortical tissue78 and thus avoiding chronic adrenal
insufficiency in case of bilateral adrenalectomy.
FOLLOW-UP
In patients with AI not surgically removed, clinical
follow-up evaluation, aimed at excluding interval
changes in tumor size or the development of hormone
overproduction, is recommended.79 There are no estab-
lished guidelines on the time schedule or method of
serial imaging and hormonal evaluation. There is gen-
eral agreement that at least one CT imaging study
should be performed 6 to 12 months after the discov-
ery of AI.79 In case of a stable mass, there are no data
supporting continued radiological evaluation, in view
of the extremely low risk of developing adrenal cortical
carcinoma as supported by longitudinal studies. When
serial radiological control evaluations are performed,
we prefer, if possible, US to CT to avoid radiation
exposure.80 Hormonal hypersecretion may develop
over time in about 20% of patients; it is generally
represented by cortisol hypersecretion, but it rarely
occurs in patients with AIs smaller than 3 cm. As the
risk of developing hypersecretion seems to plateau
after 4 years, no laboratory tests are recommended
after this period.
Finally, in patients undergoing surgery for SCS, peri-
operative glucocorticoid treatment should be ensured
to avoid postsurgical hypoadrenalism and should be
stopped only after functional recovery of the hypotha-
lamic-pituitary-adrenal axis.
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